Microarray technology is being applied to the investigation of heart disease, mental illness, infectious diseases, and cancer. It is now possible to classify cancers based on the patterns of gene activity in the tumor cells, suggesting that it will be feasible to design treatment strategies focused on specific malignancies.
According to Justin O’Kelly, a spokesperson for Affymetrix, among his company’s most notable genotyping products are the Genome-Wide Human SNP Array 6.0 and the new Genotyping Console 3.0.1 software (GTC 3.0.1).
The SNP Array 6.0 is a single microarray that measures more than 1.8 million markers for genetic variation, according to the company. It consists of 906,600 SNPs and 946,000 copy-number probes. The array enables researchers to perform whole-genome association studies by genotyping more markers from more individuals at a lower cost per sample. These studies increase the probability of discovering genes associated with adverse drug response or complex diseases such as Alzheimer’s, diabetes, heart disease, and Parkinson’s disease.
Integrating SNP genotyping, copy-number polymorphism (CNP) genotyping, and rare copy number variation identification in one data analysis application, the SNP 6.0 Array and the GTC 3.0.1 enable researchers to bridge CNP genotyping and classical SNP genotyping analysis in one genome-wide association study and/or high-resolution cytogenetic analysis, the company reports.